NEMOLIZUMAB

Brand name:

• Nemluvio®

Pharmaceutical company:

GALDERMA AUSTRALIA PTY LTD

Condition/indication:
(therapeutic use)

• Atopic dermatitis

PBAC Submission type:

New PBS listing (–)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – July 2025

Related medicines:

--

Submission received for:

July 2025 PBAC meeting

Opportunity for consumer comment:

Open 02/04/2025 and close 28/05/2025 (see PBS Website)

PBAC meeting:

Held on 09/07/2025

PBAC outcome published:

Not Recommended (see PBAC Outcomes)

Lodgement of required documentation:

Not applicable

Agreement to listing arrangements:

Not applicable

Government processes:

Not applicable

Medicine listed on the PBS:

Not applicable

---